For lung cancer, there are easy-to-use and affordable commercial panels that differ slightly but cover the important targets—EGFR, KRAS, BRAF, and MET. These panels are referred to as targeted NGS panels as they focus on hotspot regions and frequently altered genes, with a direct and known consequence on therapy, diagnosis or prognosis. This evidence concerns the gene BRAF and lung carcinoma.